Sep 2026· Molecular and Cellular Probes· Vol 90, pp.
102086
· 0 citations· 63 references
Medicine
TL;DR
This study highlights that TC metastasis is associated with significant alterations in the serum metabolite profiles of patients, and Cr and ALA play a role in inhibiting TC development, suggesting novel avenues for dietary intervention in cancer treatment.
Abstract
Background
Thyroid cancer (TC) has traditionally been regarded as an indolent malignancy. However, it retains the potential for metastasis and lethality, underscoring its status as a malignant tumor. To explore the interplay between serum metabolite profiles, gut microbial communities, and TC metastasis, we conducted a comprehensive study.
Methods
Serum metabolites were analyzed using untargeted metabolomics methods to characterize the metabolic changes. Two diet-derived metabolites, creatine (Cr) and α-linolenic acid (ALA), were selected for in vitro validation. Finally, 16S rRNA gene sequencing was used to characterize the intestinal microbial composition and analyze the correlation between differential metabolites and differential intestinal microbiota.
Results
LC-MS analysis of serum metabolites identified Arginine and proline metabolism and Arginine biosynthesis as the primary metabolic pathways altered in TC metastasis. Both Cr and ALA effectively inhibited EMT, migration, and invasion of TC cell lines, TPC1 and FTC-133. The analysis of gut microbiota composition revealed that Cr and ALA showed significant correlations with the bacteria genera, Porphyromonas and Papillibacter.
Conclusions
This study highlights that TC metastasis is associated with significant alterations in the serum metabolite profiles of patients, and Cr and ALA play a role in inhibiting TC development. Furthermore, Cr and ALA were correlated with Porphyromonas and Papillibacter, implying their potential link with food-borne components and their connected impact on TC metastasis. The findings provide new insights into the role of metabolites and gut microbiota in TC progression, suggesting novel avenues for dietary intervention in cancer treatment.
This study delineates distinct alterations in the gut microbiota and serum metabolomic profiles of EC patients, identifying Megamonas and Klebsiella as promising non-invasive predictive biomarkers.
Yu-Er Sun, Juan Li, Jia-Yu Chen et al.· Frontiers in Cellular and In...· 0 citations
The gut microbiota and its metabolites may be associated with the immune microenvironment and tumor progression in CESC, potentially involving the MIF signaling axis.
Bin Chen, Chang Xu· Applied Biochemistry and Bio...· 0 citations
Background Colorectal cancer (CRC) remains one of the major challenges in contemporary oncology. Despite advances in imaging diagnostics and histopathological assessment, we still lack tools for the early detection of micrometastases and molecular alterations. The purinergic and endocannabinoid systems play an importan...
Jakub Klekowski, Paulina Fortuna, M. Chabowski et al.· Frontiers in Oncology· 0 citations
A large-scale metabolome relative quantitative method workflow using ultrahigh-performance liquid chromatography coupled with Q-TRAP mass spectrometry to identify novel biomarkers in the serum of CC patients demonstrates applicability in identifying potential metabolite biomarkers for CC and provides a promising tool f...
Shu-Ting Yu, Gui-Fang Ye, Jia-Xin Gai et al.· Journal of Proteome Research· 0 citations
Colorectal cancer (CRC) is associated with metabolic and inflammatory disturbances, including alterations in the arginine–nitric oxide (NO) pathway. This study assessed serum metabolites related to the arginine–NO–nitrated fatty acid (NO₂-FA) axis in patients with CRC and examined their associations with tumor stag...
Jakub Klekowski, Paulina Fortuna, Ł. Lewandowski et al.· Frontiers in Molecular Biosc...· 0 citations
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), with an increasing incidence in recent years. Ouabain, a cardiotonic steroid, has demonstrated anti-tumor effects in various cancers including DLBCL, but its mechanism of action is not yet fully understood. We first used liq...
Yuan Wei, Yan-Huan Yu, Yu-Ning Zhu et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.